NPC1L1 Gene Polymorphism and the Efficacy and Safety of Hybutimibe

Not yet recruitingOBSERVATIONAL

Enrollment

1,000

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Gene PolymorphismASCVD

Interventions

DRUG

Hybutimibe 10mg QD

Hybutimibe was added to the conventional treatment

All Listed Sponsors

collaborator

Beijing Micro Love Public Welfare Foundation

UNKNOWN

lead

Qianfoshan Hospital

OTHER

NCT06641661 - NPC1L1 Gene Polymorphism and the Efficacy and Safety of Hybutimibe | Biotech Hunter | Biotech Hunter